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Objectives This study sought to evaluate the impact of new conduction defects after transcath-
eter aortic valve implantation (TAVI) on the evolution of left ventricular (LV) function during
1-year follow-up.
Background New left bundle branch block (LBBB) or need for permanent pacing due to atrioven-
tricular (AV) block are frequent after TAVI.
Methods A total of 90 consecutive patients treated with TAVI and who had 12-month echocardio-
graphic follow-up were included in the study. In 39 patients, a new conduction defect (new LBBB or
need for permanent pacemaker activity.) persisted 1 month after TAVI. In 51 patients, no persistent
new conduction defect was observed. Two-dimensional echocardiography using parasternal short-
axis, apical 4-chamber, and apical 2-chamber views was performed before TAVI and at 1-year fol-
low-up to determine LV volumes and ejection fraction based on Simpson’s rule. Speckle-tracking
echocardiography was applied using standard LV short-axis images to assess the effect of new con-
duction defects on time-to-peak radial strain of different LV segments as a parameter of LV dyssyn-
chrony.
Results New conduction defects resulted in marked heterogeneity in time-to-peak strain between
the 6 analyzed short-axis segments. During 1-year follow-up after TAVI, there was a signiﬁcant in-
crease in left ventricular ejection fraction (LVEF) in patients without new LBBB (53  11% pre TAVI
o 59  10% at follow-up; p  0.001), whereas there was no change in LVEF in patients with a new
onduction defect (52  11% pre TAVI to 51  12% at follow-up, p  0.740). Change in LV end-
systolic volume was also signiﬁcantly different between patient groups (1.0  14.2 vs. 11.2 
15.7 ml, p  0.042). New conduction defect and LVEF at baseline were independent predictors of
reduced LVEF at 12-month follow-up after TAVI.
Conclusions LVEF improves after TAVI for treatment of severe aortic stenosis in patients without
new conduction defects. In patients with a new conduction defect after TAVI, there is no improve-
ment in LVEF at follow-up. (J Am Coll Cardiol Intv 2012;5:1257–63) © 2012 by the American
College of Cardiology Foundation
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1258Transcatheter aortic valve implantation (TAVI) has become
a therapeutic option for high-risk or nonoperable patients
with severe symptomatic aortic valve stenosis (1–6). A
major limitation of TAVI is the frequent occurrence of new
conduction defects and a subsequent need for pacemaker
implantation (7–11). Pressure induced by the procedure and
by the valve implant on the atrioventricular (AV) bundle
located close to the aortic valve has been discussed as the
reason for new conduction defects. The frequency of new
left bundle branch blocks (LBBB) and the need for pace-
maker implantation is known to be higher with the self-
expanding CoreValve prosthesis (Medtronic, Minneapolis,
Minnesota) than with the balloon-expandable Edwards
SAPIEN valve (Edwards Lifesciences, Irvine, California).
LBBB is known to be associated with left ventricular (LV)
dyssynchrony, ventricular remodeling, and impaired func-
tion (12). Implantation of a permanent right ventricular
pacemaker (PPM) is also known to result in impairment of
LV function (13–15). The cause of the deleterious effect of
PPM has been shown to be LV dyssynchrony (15). Al-
though LV dyssynchrony is the
consequence of a new LBBB or
a PPM after TAVI, the impact
of a new conduction defect after
TAVI on the development of LV
function during 1-year follow-up
has not been evaluated.
Myocardial deformation im-
aging using speckle-tracking
echocardiography for radial
strain analysis allows detection
of LV dyssynchrony (16,17). We
hypothesized that the induction
of a new conduction defect after
AVI induces LV dyssynchrony and has a negative impact
n LV function.
The current study: 1) used speckle-tracking echocardiog-
aphy to determine the impact of a new conduction defect
fter TAVI on heterogeneity of LV contraction; 2) analyzed
he impact of a new conduction defect after TAVI on LV
olumes and ejection fraction at 12-month follow-up; and
) determined predictors of failed recovery of LV function
t 12-month follow-up after TAVI.
ethods
Study design and patient population. We prospectively
valuated 125 consecutive patients (39 male, mean age 81
years) with severe symptomatic calcified native valve
tenosis in whom either a CoreValve or Edwards SAPIEN
evalving system was implanted between January 2009 and
uly 2010 and in whom 1-year follow-up echocardiography
as aimed for. Twenty-seven patients died during 1-year
Abbreviations
and Acronyms
AV  atrioventricular
LBBB  left bundle branch
block
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
PPM  permanent
pacemaker
TAVI  transcatheter aortic
valve implantationollow-up. Another 8 patients refused to return forollow-up echocardiography. In 90 patients, echocardiogra-
hy was performed before TAVI, at 1 month, and at 1-year
ollow-up. These patients formed the study group. Patients
ere referred for percutaneous aortic valve implantation
fter a senior cardiologist and senior cardiac surgeon
eached consensus that surgical replacement would be asso-
iated with either high or prohibitive risk. The inclusion
nd exclusion criteria of patients for implantation of the
atheter-based revalving systems have been described else-
here (9). In patients with significant femoral or iliac artery
isease, transapical TAVI was the preferred procedure,
hereas transfemoral TAVI was preferred in very old
atients and in patients with pulmonary disease. Patients
ad to have a valve area 1 cm2, and aortic valve annulus
diameter measuring 18 and 27 mm. Presence of a
icuspid aortic valve as defined by echocardiographic
creening was an exclusion criteria for TAVI. This study
as approved by the ethical committee of the University
achen, and all patients gave informed consent.
Description of the device and the procedure. In 52 patients
58%), the CoreValve Revalving system was used. In 38
atients (42%), the Edwards SAPIEN valve was implanted.
etails of the devices, and the technical aspects of the
rocedure, have been previously published (1–4). The
oreValve Revalving system consists of a self-expanding
itinol trilevel frame to which a trileaflet bioprosthetic
orcine pericardial tissue valve is secured. In this study,
rosthesis sizes of 26 and 29 mm have been used. The
dwards SAPIEN valve is a balloon-expandable, bovine
ericardium prosthesis. In this study, prosthesis sizes of 23
nd 26 mm have been used. All patients treated by apical
ccess TAVI obtained an Edwards SAPIEN valve, whereas
ll patients treated by femoral access TAVI obtained a
oreValve Revalving system device. Selection of the device
ize was based on measurements of the aortic root anatomy
nd aortic valve measurements, in particular the aortic valve
nnulus diameter, obtained by transesophageal echocardi-
graphy, calipered angiography, and multislice computed
omography. Selection of prosthesis size intended slight
versizing of the prosthesis diameter relative to the annulus
iameter to securely fix the prosthesis within the native valve
nd annulus, and minimize the potential for paravalvular
eaks between the prosthetic valve and native annulus.
Balloon valvotomy was performed before implantation.
ositioning and deployment of the device was performed
nder fluoroscopic guidance using the CoreValve prosthesis
nd with combined fluoroscopic and transesophageal echo-
ardiography guidance for Edwards SAPIEN implantation.
Echocardiography. Pre-interventional patient screening in-
cluded transthoracic as well as transesophageal echocardi-
ography to confirm diagnosis, define aortic valve morphol-
ogy, and measure the aortic valve annular diameter.
Follow-up echocardiography was performed at 1 month
and at 12 months. Echocardiography at baseline and at
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125912-month follow-up was used to evaluate LV end-diastolic
and end-systolic volumes based on apical 4- and 2-chamber
views and application of the Simpson’s method. The LVEF
was calculated based on LV volume measurements. Echo-
cardiography at baseline and at 1-month follow-up was
performed to evaluate myocardial deformation.
Myocardial deformation analysis. Speckle-tracking analysis
was performed on LV short-axis images at the papillary
muscle level to determine radial strain (17). Off-line analysis
of radial strain was performed on digitally stored images
(EchoPAC, GE Vingmed, Horton, Norway) by 2 indepen-
dent observers blinded to the clinical and other echocardio-
graphic information. The speckle-tracking software tracks
natural acoustic markers frame to frame on grayscale images
of the myocardium (frame rate varied from 40 to 80
frames/s), as previously described (17). Myocardial strain is
determined from temporal differences in the mutual dis-
tance of neighboring speckles. Radial strain is calculated as
change in length/initial length of the speckle pattern over
the cardiac cycle, with myocardial thinning represented as
negative strain and myocardial thickening as positive strain.
The traced endocardium is automatically divided into 6
standard segments: septal, anteroseptal, anterior, lateral,
posterior, and inferior (17). For all 6 segments, time-strain
curves were constructed. Time from QRS onset to peak
radial strain was obtained for each curve. The location of the
earliest- and latest-activated segments and the heterogeneity
in time-to-peak radial strain for the 6 segments was deter-
mined. The time difference between the earliest- and
latest-activated segment was calculated. An interval 130
ms for the absolute difference in time-to-peak radial strain
for the septal or anteroseptal wall versus the posterior or
lateral wall was defined as LV dyssynchrony (17). On
short-axis images of 20 randomly selected patients, intra-
and interobserver variability in the analysis of time-to-peak
radial strain were determined. The intraobserver variability
for determining the time-to-peak radial strain of all 6
segments was 12  9 ms, and the interobserver variability
5  11 ms.
Electrocardiography and pacemaker requirements. Electro-
cardiographic tracings obtained before and after valve im-
plantation, along with 1-month follow-up recordings, were
interpreted in the core laboratory at the University Aachen.
Serial electrocardiographic recordings were performed
within the first 5 days after the TAVI procedure. The
recordings were analyzed for rhythm, heart rate (beats/min),
PQ and QRS intervals (in milliseconds), and presence of
second- or third-degree AV block. The requirements after
the procedure for a temporary pacemaker or PPM were
documented. A PPM was implanted based on PQ and QRS
interval measurements and serial changes within the first
days after the procedure. A deliberate approach towards
PPM implantation was applied. Registration of intermittent
second- or third-degree AV block was an indication for pPPM implantation. A QRS interval130 ms together with
a PQ interval 250 ms was also used as an indication for
PPM implantation unless serial studies indicated a reduc-
tion of intervals immediately after TAVI.
On the basis of the 1-month follow-up ECG, patients
were divided into those without any new electrocardio-
graphic conduction defects and those with a new conduction
defect. Documentation of either a new LBBB or the new
need for PPM action due to total AV block determined the
presence of a new conduction defect.
Statistical analysis. Statistical analysis was performed using
the SPSS software version 17.0 (IBM, Armonk, New
York). Categorical data were presented as frequencies and
compared with the Pearson chi-square test. Continuous
data were presented as mean  SD and compared with the
tudent t test or analysis of variance as appropriate. Logistic
egression analysis was performed to identify univariate and
ultivariate predictors for a reduction of left ventricular
jection fraction (LVEF) at 12-month follow-up (LVEF
ollow-up minus LVEF before TAVI 0%). Included
ariables were age, sex, aortic valve area before TAVI,
VEF at baseline, number of significantly diseased coronary
rteries on angiography, severity of aortic regurgitation after
AVI, type of implanted TAVI device (either the self-
xpanding CoreValve or the balloon-expandable Edwards
APIEN), and a new conduction defect after TAVI.
nivariate predictors with p  0.20 were included in the
ultivariate analysis. In addition, an analysis of covariance
as performed to determine in a multiple linear regression
odel factors with impact on change in LVEF during
2-month follow-up. p  0.05 was considered statistically
ignificant.
esults
In 90 patients, baseline, 1-month, and 12-month follow-up
echocardiography was obtained. Fifteen of these patients
had atrial fibrillation (17%) at baseline, and 12 patients
(13%) had baseline conduction defects. In 7 patients, there
was an LBBB, and 5 patients had PPM action due to AV
block.
Frequency of new conduction deﬁcit. Thirty-nine patients
43%) had a new conduction defect after TAVI, and in 51
atients (57%), no new conduction defect was documented.
hirty-one patients (35%) had a new LBBB. Twelve of
hese 31 patients with new LBBB had a new PPM
mplanted but only intermittent pacemaker action. An
dditional 8 patients (9%) had new need for PPM activation
ue to complete AV block after TAVI. In 3 of the 51
atients considered to have no new conduction defect, a new
PM was implanted due to documentation of intermittent
V block immediately after TAVI. However, at 1-month
ollow-up, pacemaker analysis documented only sporadic
acemaker action.
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1260Baseline and procedural characteristics of patients with
new conduction defects as compared with patients without
new conduction defects are given in Table 1. In 32 of the 52
CoreValve patients (62%) and in 7 of the 38 Edwards
SAPIEN patients (18%), a new conduction defect was
observed after the procedure. Thus, the frequency of new
conduction defects was significantly higher after CoreValve
implantation compared with Edwards SAPIEN implanta-
tion (p  0.001).
LV volumes and LVEF. At baseline before TAVI, there were
o differences in LV end-diastolic and end-systolic volumes
s well as LVEF between patients with new and those
ithout new conduction defects after TAVI (Table 2). At
2-month follow-up, LV end-systolic volume had de-
reased for the total study population from 65 31 to 60
1 ml (p  0.039), whereas end-diastolic volume was
nchanged (136  51 vs. 135  50 ml). Patients without
ew conduction defects after TAVI had a significantly
Table 1. Patient Baseline and Procedural Characteristics
New Conduction
Disturbance
(n  39)
No New Conduction
Disturbance
(n  51) p Value
Age, yrs 80 6 79 6 0.422
Male 14 (36) 20 (40) 0.387
Log EuroSCORE 21 13 19 12 0.324
NYHA functional class 3.1 0.6 3.0 0.6 0.535
CAD 25 (65) 34 (67) 0.848
PAH 6 (16) 9 (18) 0.778
Mitral regurgitation grade 2 11 (27) 13 (26) 0.921
GFR 60 ml/min 12 (29) 22 (43) 0.172
TAVI type
Edwards SAPIEN 7 31 0.001
CoreValve 32 20
Values are n, n (%), or mean SD.
CAD  coronary artery disease; GFR  glomerular filtration rate; NYHA  New York Heart
Association; PAH pulmonary artery hypertension (mean pressure25 mm Hg); TAVI trans-
catheter aortic valve implantation.
Table 2. LV Volumes and LVEF Before TAVI and at 12-Month Follow-Up
Related to New Conduction Disturbance
New Conduction
Disturbance
(n  39)
No New Conduction
Disturbance
(n  51) p Value
ESV before TAVI, ml 64 31 65 30 0.771
∆ ESV at follow-up, ml 1.0 14.2 11.2 15.7 0.042
EDV before TAVI, ml 136 46 134 54 0.843
∆ EDV at follow-up, ml 3.3 25.2 7.5 27.2 0.374
LVEF before TAVI, % 52 11 53 11 0.854
LVEF at follow-up, % 51 12 59 10 0.052
∆ LVEF at follow-up, % 0.5 9.4 5.8 7.9 0.002
Values are mean SD or % SD.
EDV  end-diastolic volume; ESV  end-systolic volume; LV  left ventricular; LVEF  leftventricular ejection fraction; TAVI transcatheter aortic valve implantation.maller end-systolic volume at 12-month follow-up com-
ared with patients with new conduction defects (Table 2).
hanges in end-diastolic LV volumes were less different
etween patients with and without new conduction defects.
he LVEF changed at 12-month follow-up after TAVI
rom 54  11% to 57  11% for the total study group. In
atients without new conduction defects, there was an
ncrease in LVEF of 5.8  7.9% (p  0.001 for LVEF at
ollow-up vs. baseline), whereas there was almost no change
t 12-month follow-up in the group with new conduction
efects (0.5  9.4%, p  0.740 between baseline and
ollow-up) (Fig. 1). Eight patients (16%) of the no new
onduction defect group demonstrated impairment of
VEF at follow-up, whereas 19 patients (49%) in the new
onduction defect group demonstrated impairment of
VEF at follow-up. Thus, there was a significant difference
etween both groups in the change of LVEF at follow-up
p  0.002). Considering only CoreValve patients, LVEF
ncreased by 1.7  10.4%, whereas LVEF increased by
.4  6.8% in Edwards SAPIEN patients (p  0.230).
Myocardial deformation analysis. At baseline, there was a
high level of homogeneity in the time-to-peak radial strain
between the 6 analyzed segments of a short-axis image. At
baseline, there was also no difference between patients with
and without new conduction defects after TAVI in the
homogeneity of LV contraction expressed as the time differ-
ence between earliest and latest segment reaching the peak
radial strain (Table 3). One month after TAVI, the time
difference between the earliest and latest peak radial strain
reached in the 6 segments of 1 short-axis image had
40
45
50
55
60
65
Before TAVI 12 Months Follow-up
53±11
52±11
59±10
51±12
LVEF (%)
p=0.740 
P<0.001
Figure 1. LVEF at Baseline and at Follow-Up
Solid line represents the group of patients with new conduction defects
after TAVI; dashed line represents the group of patients without new con-
duction defects. LVEF  left ventricular ejection fraction; TAVI  transcath-
eter aortic valve implantation.increased significantly from 43  39 to 142  52 ms (p 
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12610.001) in the new conduction defect group. By contrast,
there was no significant change in the no new conduction
defect group. At 1 month after TAVI, the time difference
between earliest and latest segment reaching the peak radial
strain was found to be significantly different between the
groups with and without new conduction defects (Table 3).
Considering the definition for LV dyssynchrony based on
absolute difference in time-to-peak radial strain for the
septal or anteroseptal wall versus the posterior or lateral
wall, 34 patients (87%) were found to have LV dyssyn-
chrony in the new conduction defect group at 1-month
follow-up after TAVI and 5 patients (10%) in the no new
conduction defect group.
Predictors of impaired LV function after TAVI. In a univariate
ogistic regression analysis induction of a new conduction
efect, LVEF at baseline and the time difference to peak
adial strain 1 month after TAVI were univariate predictors of
reduction in LV function at 12-month follow-up (Table 4).
n a multivariate logistic regression analysis, new conduction
efect (odds ratio: 2.001, 95% confidence interval: 1.271 to
.045, p  0.003) and LVEF at baseline (odds ratio: 1.010,
5% confidence interval: 1.001 to 1.019, p  0.021)
emained independent predictors of a reduction in LV
unction at 12-month follow-up. Age, sex, aortic valve area
efore TAVI, prosthesis diameter, and aortic regurgitation
ere not independent predictors of impaired LVEF at
ollow-up. Considering a covariance analysis, only LVEF at
aseline (regression coefficient b: 0.271, p  0.001) as a
ovariate and new conduction defect (adjusted mean differ-
nce: 5.595, p  0.001) had influence on change in LVEF
t 12-month follow-up.
iscussion
The main findings of this study are: 1) TAVI is frequently
associated with new conduction defects; 2) patients with
new conduction defects demonstrate dyssynchrony in LV
function 1 month after TAVI; 3) although there is improve-
ment in LVEF after TAVI for severe aortic stenosis in
patients without new conduction defects, patients with new
Table 3. Analysis of LV Contraction Synchrony Using Echocardiographic
Deformation Imaging
New
Conduction
Disturbance
(n  39)
No New
Conduction
Disturbance
(n  51) p Value
Pre-TAVI ∆ time-to-peak systolic
radial strain, ms
36 24 29 22 0.101
1-month post-TAVI ∆ time-to-peak
systolic radial strain, ms
139 35 38 34 0.001
Values are mean SD. Time-to-peak systolic radial strain relates to the time difference to peak
systolic strain between the 6 analyzed segments of the short axis image.
Abbreviations as in Table 2.conduction defects have a significantly worse developmentin LV function at 12-month follow-up; and 4) development
of a new conduction defect is a predictor of absent improve-
ment in LV function at 12-month follow-up.
Conduction defects after TAVI. New conduction defects
evelop in as many as one-third of patients undergoing
urgical replacement of the aortic valve, with LBBB being
he most common abnormality (18–20). After TAVI, new
onduction defects have been described in an even signifi-
antly higher number of patients, with new LBBB being the
redominant new conduction defect (7–11,21–24). The
natomic neighborhood of the aortic valve to the atrioven-
ricular bundle; degeneration of the conduction system;
rauma by guidewires, catheters, and pre-implantation bal-
oon valvuloplasty; and direct constant pressure of the
mplanted valve on the left bundle branch at the base of the
nterleaflet triangle between the right and noncoronary
riangle are the potential causes (25). The frequency of new
BBB has been reported to be higher after implantation of
he CoreValve prosthesis as compared with the Edwards
APIEN prosthesis (24). This has been explained by the
larger size of the CoreValve prosthesis and, in particular, the
greater depth of implantation within the LV outflow track.
An implantation depth into the LV outflow track 6 mm
has been associated with a significantly increased risk of
LBBB (7,24). In a study on 30 patients treated with a
CoreValve prosthesis, Calvi et al. (10) observed a frequency
of early conduction disorders after TAVI in 68% of patients.
LBBB was the most common conduction abnormality, with
an incidence of 45.8%. In a study on 40 consecutive patients
in whom a CoreValve device was implanted, the frequency
of LBBB increased from 15% before treatment to 55% after
valve implantation (7). In a recent study on 270 patients, the
incidence of LBBB was reported to be 13% before TAVI
and 61% after TAVI using the CoreValve prosthesis (25).
New-onset LBBB has been reported with lower frequency
after implantation of Edwards SAPIEN valve. Gutiérrez et
al. (11) reported an increase in the frequency of LBBB from
9% at baseline to 27% after Edwards SAPIEN implanta-
tion. Need for PPM implantation after TAVI has been
reported in up to 39.3% of patients in a registry of 697
patients (26). Significantly higher rates of pacemaker re-
quirement have been reported after CoreValve implantation
Table 4. Univariate Predictors of Reduced LVEF at 12-Month Follow-Up
After TAVI
OR 95% CI p Value
New LBBB or new PPM 1.551 1.294–1.844 0.001
1-month post-TAVI ∆ time-to-peak systolic
radial strain (per additional ms)
1.003 1.001–1.005 0.001
LVEF before TAVI (per additional %) 1.012 1.003–1.022 0.007
LVEF at 12-month follow-up minus LVEF at baseline0%.
CI confidence interval; LBBB left bundle branch block; OR odds ratio; PPM permanentpacemaker; other abbreviations as in Table 2.
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1262compared with after Edwards SAPIEN implant. Khawaja et
al. (25) reported in a study of 270 patients a PPM rate of
33.3%, and Piazza et al. (7) reported in a smaller study a rate
of 40% after CoreValve implantation. By contrast, need for
a new PPM has been reported to be as low as 3.4% and
3.8%, respectively, in both arms of the PARTNER (Place-
ment of Aortic Transcatheter Valve) trial involving a total of
527 TAVI patients with an Edwards SAPIEN implant
(4,27).
LV function after TAVI. LV function is known to improve
fter aortic valve replacement for severe aortic stenosis.
urthermore, better post-procedural recovery of LVEF has
een shown to be associated with better improvement in
unctional status and better late survival (28). Inconsistent
esults have been reported after TAVI. Some studies have
lso documented improvements in LVEF after TAVI
29,30). In a study comparing the development of LV
unction between patients undergoing transcatheter and
urgical prosthetic valve implantation, TAVI patients had
ven better recovery of LVEF at 1 year (28). However, in
his study as well as others demonstrating improvement in
VEF after TAVI, the Edwards SAPIEN valve was used
or the procedure. By contrast, studies reporting on the
evelopment of LVEF after implantation of the CoreValve
rosthesis did not demonstrate significant improvement
31). The different rates of conduction defects, and in
articular LBBB, may be the likely explanation for the
ifferent development of LVEF after TAVI using Edwards
APIEN versus CoreValve implants.
This study evaluated the important link between new
onduction defects and subsequent development of LV
unction. New conduction defects resulted immediately in
V dyssynchrony. At 12-month follow-up, patients with
ew conduction defects had significantly worse develop-
ent of the LV function than patients without new con-
uction defects. The impact of PPM action on ventricular
ynchrony and development of LV function has been
emonstrated in several trials (13–15). Tops et al. (15)
demonstrated that patients with new LV dyssynchrony with
PPM action had a decrease in LVEF from 48% at baseline
to 39% at 1-year follow-up. Previous studies have demon-
strated that the cumulative percent right ventricular pacing
increased the risk of heart failure and risk of death.
Although in previous studies on right ventricular pacing, the
implantation of the device induced only deleterious effects,
TAVI results in a potentially positive impact on LV
function due to afterload reduction and, simultaneously, the
deleterious effect of LV dyssynchrony due to new conduc-
tion defects. The induction of a new conduction defect and
its impact on LV function may be of limited importance in
the very old, high-risk patients receiving TAVI. However,
in the moderate surgical risk patient of lower age, increas-
ingly treated with TAVI, the effect of new conductiondefects may be of greater importance for subsequent patient
outcome.
Study limitations. This is a single-center experience. Fur-
ther studies with higher patient numbers will be necessary to
further assess the development of LV volumes and function
after TAVI. Future studies need to assess the impact of new
conduction defects on patient functional class and life
quality. The indication for pacemaker implantation did not
follow strict rules after TAVI. Thus, some patients may
have received “prophylactic” pacing in the presence of
LBBB in combination with prolonged PQ interval. How-
ever, only patients with PPM action at 1-month follow-up
were included in the group with new conduction defects.
This study did not demonstrate a significant difference in
the change of LV function at follow-up between patients
treated with a CoreValve prosthesis and those treated with
an Edwards SAPIEN prosthesis although there was a
significantly higher rate of new conduction defects after
implantation of the CoreValve prosthesis. A randomized
study with higher patient numbers may be required to
evaluate a potential difference in LV function at follow-up
between both valve types. This study did not find the access
site to be a predictor of impairment in LV function at
follow-up. However, the apical access TAVI may result in
minor apical scar formation and thus impairment of LV
function at follow-up.
Conclusions
TAVI is frequently associated with new conduction defects.
New conduction defects result in LV dyssynchrony and
subsequently impaired development of LV function at
12-month follow-up.
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